Predicted protein targets (top 19)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | AKR1C3 | P42330 | 12/20 | 1.00 |
| ▸ | AKR1C2 | P52895 | 12/20 | 1.00 |
| ▸ | PTGS1 | P23219 | 3/20 | 1.00 |
| ▸ | AKR1C1 | Q04828 | 2/20 | 1.00 |
| ▸ | PTGS2 | P35354 | 3/20 | 0.65 |
| ▸ | TSHR | P16473 | 2/20 | 0.65 |
| ▸ | CDC42 | P60953 | 1/20 | 0.65 |
| ▸ | RAC1 | P63000 | 1/20 | 0.65 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.65 |
| ▸ | SLC22A6 | Q4U2R8 | 1/20 | 0.65 |
| ▸ | AKR1B10 | O60218 | 1/20 | 0.54 |
| ▸ | AKR1C4 | P17516 | 1/20 | 0.54 |
| ▸ | ABCB11 | O95342 | 1/20 | 0.54 |
| ▸ | LMNA | P02545 | 1/20 | 0.54 |
| ▸ | MAPT | P10636 | 1/20 | 0.54 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.54 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.52 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.52 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.50 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL24991971 | 1.00 | AKR1C3 (1.00) | AKR1C3AKR1C2PTGS1AKR1C1PTGS2 | |
| SCHEMBL506301 | 1.00 | AKR1C3 (1.00) | AKR1C3AKR1C2PTGS1AKR1C1PTGS2 | |
| SCHEMBL3043390 | 1.00 | AKR1C3 (1.00) | AKR1C3AKR1C2PTGS1AKR1C1PTGS2 | |
| SCHEMBL32670176 | 1.00 | AKR1C3 (1.00) | AKR1C3AKR1C2PTGS1AKR1C1PTGS2 | |
| SCHEMBL32670173 | 1.00 | AKR1C3 (1.00) | AKR1C3AKR1C2PTGS1AKR1C1PTGS2 | |
| SCHEMBL506524 | 0.88 | AKR1C3 (0.78) | AKR1C3AKR1C2PTGS1AKR1C1PTGS2 | |
| SCHEMBL11157532 | 0.88 | AKR1C3 (0.78) | AKR1C3AKR1C2PTGS1AKR1C1PTGS2 | |
| SCHEMBL11161413 | 0.88 | AKR1C3 (0.78) | AKR1C3AKR1C2PTGS1AKR1C1PTGS2 | |
| SCHEMBL9560269 | 0.88 | AKR1C3 (0.78) | AKR1C3AKR1C2PTGS1AKR1C1PTGS2 | |
| SCHEMBL15535590 | 0.86 | AKR1C3 (0.76) | AKR1C3AKR1C2PTGS1AKR1C1PTGS2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-4357346-A1 | EXTERNAL ANTI-INFLAMMATORY COUPLING COMPOUND DRUG, AND PREPARATION METHOD THEREFOR AND USE THEREOF | Coval Biopharma (Shanghai) Co., Ltd. (CN) | 2024-04-24 | — | — | EP | disclosed |
| US-20210277050-A1 | OPHTHALMIC COMPOSITIONS AND METHODS FOR THE TREATMENT OF EYE DISORDERS | CELLIX BIO PRIVATE LIMITED (IN) | 2021-09-09 | — | — | US | disclosed |
| US-20120029226-A1 | METHOD FOR THE SYNTHESIS OF CHIRAL ALPHA-ARYL PROPIONIC ACID DERIVATIVES | DSM IP ASSETS B.V. (NL) | 2012-02-02 | — | — | US | disclosed |
| US-6365398-B1 | REACTING RACEMIC CARBOXYLIC ACID ESTER WITH RACEMIC ALCOHOL IN PRESENCE OF A CARBOXYL ESTER HYDROLASE | BASF AKTIENGESELLSCHAFT (DE) | 2002-04-02 | — | — | US | disclosed |
| EP-0081993-B1 | OPTICALLY ACTIVE ALPHA-SUBSTITUTED ARYL KETONES, THEIR PREPARATION AND THEIR USE IN PREPARING ALPHA-ARYLALKANOIC ACIDS | SYNTEX PHARMACEUTICALS INTERNATIONAL LIMITED (BM) | 1988-08-17 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120029226-A1 | METHOD FOR THE SYNTHESIS OF CHIRAL ALPHA-ARYL PROPIONIC ACID DERIVATIVES | GRIA1, GRIA3, GRIA2 | AKR1C3 233/4885AKR1C2 273/4885PTGS1 1036/4885 |
| US-20210277050-A1 | OPHTHALMIC COMPOSITIONS AND METHODS FOR THE TREATMENT OF EYE DISORDERS | F5, OR10J3, SHBG | AKR1C3 756/4885AKR1C2 492/4885PTGS1 679/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.